淋巴瘤介绍

弥漫大B细胞淋巴瘤(DLBCL) 套细胞淋巴瘤(MCL) 外周T细胞淋巴瘤(PTCL) 血管免疫母细胞T细胞(AITCL) 原发性中枢神经系统(PCNSL) T/NK 细胞淋巴瘤(NK/TCL) 滤泡型NHL淋巴瘤(FL) 胃MALT淋巴瘤 非胃MALT淋巴瘤(NGMLT) 脾边缘带B细胞淋巴瘤(SPLN) 间变性大细胞淋巴瘤(ALCL) 皮肤T细胞淋巴瘤(CTCL)

淋巴瘤诊断

淋巴瘤治疗

淋巴瘤研究

本页主要内容有：

1.MCL介绍

2. MCL的诊断治疗指导方针

• 诊断治疗指导方针
• 推荐化疗方案

 

1. MCL介绍

---

套细胞淋巴瘤是一个很独特的类型。虽然归结在侵袭性类型里面，但是它可以表现为侵袭性和惰性两种。在部分病人中表现得和其他惰性一样，可以在较长时间内不需要治疗。在过去，这种类型的淋巴瘤预后很不好，但是随着最近治疗的研究有了很大改善。使用HyperCVAD+R代替CHOP+R后，很多病人都获得了长期完全缓解。

下面是最新的关于治疗套细胞淋巴瘤的相关文献摘要：

1. 二期临床研究改进的Hyper-CVAD 联合美罗华维持治疗治疗未经过治疗的初始套细胞淋巴瘤病人
2. Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL)
3. Autologous vs Allogeneic Cell Transplantation for Mantle Cell Lymphoma (MCL): Outcomes over a 10-Year Period at City of Hope
4. Outcomes of Autologous and Allogeneic BMT for Mantle Cell Lymphoma
5. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma
6. Allogeneic Hematopoietic Cell Transplantation after Fludarabine and 2 Gy Total Body Irradiation for Relapsed and Refractory Mantle Cell Lymphoma.
7. Thalidomide and Rituximab Effective for Mantle Cell Lymphoma Researchers from Austria have reported that the combination of thalidomide and rituximab is effective for the treatment of relapsed/refractory mantle cell lymphoma with a low toxicity profile. The details of this study appeared in the October 15, 2004 issue of Blood
8. Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission Significantly Prolongs Progression-Free Survival in Mantle Cell Lymphoma
9. Rituximab/Chemotherapy Induction Treatment Followed by High-Dose Therapy and Autologous Transplantation in Patients with Mantle Cell Lymphoma
10. Rituximab and Stem Cell Transplantation Produces Durable Remissions in Mantle Cell Lymphoma
11. Eradication of Minimal Residual Disease during Treatment of Mantle Cell Lymphoma
12. A Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin?) for Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL)
13. Phase II Trial of Bortezomib in Mantle Cell Lymphoma
14. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network

MCL Resource 是一个专门介绍套细胞淋巴瘤的网站。可以去该网站查看更详细的内容。

 

2. MCL的诊断治疗指导方针 

---

 诊断治疗指导方针

 

推荐的化疗方案

一线方案

• R+CHOP( 对于部分不能接受大强度化疗的老年患者）
• R+HyperCVAD
• R+EPOCH

一线巩固治疗方案

• 自体造血干细胞移植
• 临床试验中包括异体移植（非骨髓清除或骨髓清除）

二线方案

• Bortezomib(万珂)
• Cladribine (克拉屈滨）
• FCMR±美罗华维持治疗
• FMR
• FC±R
• PCR
• Thalidomide+R

 

 

回到顶部

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

·Copyright· All Rights Reserved

Email:lyell.li@gmail.com